A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants☆
References (28)
- et al.
Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy
J Neurol Sci
(1997) - et al.
Homocysteinemia due to folate deficiency
Metabolism
(1987) - et al.
Relationship between homocysteine and thrombotic disease
Am J Med Sci
(1998) - et al.
Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants
Metabolism
(1997) - et al.
Mortality from epilepsy: Results from a prospective population-based study
Lancet
(1994) - et al.
The 677 C → T mutation in the methylenetetrahydrofolate reductase gene: Associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease
Atherosclerosis
(1997) - et al.
Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida
Lancet
(1995) - et al.
Homocysteine metabolism in pregnancies complicated by neural tube defects
Lancet
(1995) - et al.
Drags and folate metabolism
Drugs
(1985) - et al.
A comparative study of the relative effects of anticonvulsant drugs and dietary folate on the red cell folate status of patients with epilepsy
Q J Med
(1987)
Interactions between folates and carbamazepine or valporate in the rat
Neurology
(1982)
Decreased hepatic 5,10-methylenetetrahydrofolate reductase activity in mice after chronic phenytoin treatment
Mol Pharmacol
(1984)
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes
JAMA
(1995)
Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drag therapy
J Lab Clin Med
(1989)
Cited by (0)
- ☆
Supported by the research fund of Samsung Biomedical Research Institute (C-98-029) and Samsung Medical Center.
Copyright © 1999 Published by Elsevier Inc.